Cargando…

Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy

Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yinghua, Fan, Xiang, Yu, Zhanyang, Liao, Zhengbu, Wang, Xiao-Shu, van Leyen, Klaus, Sun, Xiaochuan, Lo, Eng H., Wang, Xiaoying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604305/ https://www.ncbi.nlm.nih.gov/pubmed/26528130 http://dx.doi.org/10.3389/fncel.2015.00397

Ejemplares similares

Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice
por: Cheng, Chongjie, et al.
Publicado: (2021)

Thrombospondin-1 Gene Deficiency Worsens the Neurological Outcomes of Traumatic Brain Injury in Mice
por: Cheng, Chongjie, et al.
Publicado: (2017)

The Impact of Loading Dose on Outcome in Stroke Patients Receiving Low-Dose Tissue Plasminogen Activator Thrombolytic Therapy
por: Wong, Yi-Sin, et al.
Publicado: (2020)

Endothelial Regulation by Exogenous Annexin A1 in Inflammatory Response and BBB Integrity Following Traumatic Brain Injury
por: Liu, Han, et al.
Publicado: (2021)

Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation
por: Ma, Yunn-Hwa, et al.
Publicado: (2019)

Annexin A2 Deficiency Exacerbates Neuroinflammation and Long-Term Neurological Deficits after Traumatic Brain Injury in Mice
por: Liu, Ning, et al.
Publicado: (2019)

Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses
por: Bäumer, Wolfgang, et al.
Publicado: (2013)

Review of Stroke Thrombolytics
por: Bivard, Andrew, et al.
Publicado: (2013)

Development and Testing of Thrombolytics in Stroke
por: Nikitin, Dmitri, et al.
Publicado: (2021)

Urokinase vs Tissue-Type Plasminogen Activator for Thrombolytic Evacuation of Spontaneous Intracerebral Hemorrhage in Basal Ganglia
por: Li, Yuqian, et al.
Publicado: (2017)

Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial
por: Zhang, Chun-Yang, et al.
Publicado: (2020)

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report
por: Ohtani, Toshiyuki, et al.
Publicado: (2019)

Successful salvage of thrombosed arterio-venous fistula with thrombolytic therapy using tissue plasminogen activator
por: Parameswaran, S., et al.
Publicado: (2015)

HDAC3 inhibition prevents blood-brain barrier permeability through Nrf2 activation in type 2 diabetes male mice
por: Zhao, Qiuchen, et al.
Publicado: (2019)

Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke
por: Zhai, Mingfeng, et al.
Publicado: (2023)

Retrospective Evaluation of the Results of Low-Dose Intravenous Thrombolytic Therapy in Acute Ischemic Stroke
por: Cetiner, Mustafa, et al.
Publicado: (2023)

Thrombolytic Therapy for Acute Stroke: The Hidden Dimension
por: Mansour, Ossama, et al.
Publicado: (2010)

Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke
por: Alhadid, Kenda, et al.
Publicado: (2023)

Acute Thrombolytic Therapy Combined with the Green Channel Can Reduce the Thrombolytic Time and Improve Neurological Function in Acute Stroke Patients
por: Hong, Zhen, et al.
Publicado: (2022)

Successful thrombolytic therapy with recombinant tissue-type plasminogen activator for massive pulmonary embolism -A case report-
por: Kim, Min Soo, et al.
Publicado: (2010)

Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy
por: Huang, Yu, et al.
Publicado: (2021)

Evolution of the Thrombolytic Treatment Window for Acute Ischemic Stroke
por: Stemer, Andrew, et al.
Publicado: (2010)

Computational Simulations of Thrombolytic Therapy in Acute Ischaemic Stroke
por: Piebalgs, Andris, et al.
Publicado: (2018)

Author Correction: Neuroglobin promotes neurogenesis through Wnt signaling pathway
por: Yu, Zhanyang, et al.
Publicado: (2019)

Neuroglobin promotes neurogenesis through Wnt signaling pathway
por: Yu, Zhanyang, et al.
Publicado: (2018)

Different Doses of Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: A Network Meta-Analysis
por: Li, Bing-Hu, et al.
Publicado: (2022)

Change of Serum Biomarkers to Post-Thrombolytic Symptomatic Intracranial Hemorrhage in Stroke
por: Cui, Yu, et al.
Publicado: (2022)

Knowledge of Thrombolytic Therapy for Acute Ischemic Stroke among Community Residents in Western Urban China
por: Yang, Juan, et al.
Publicado: (2014)

New Thrombolytic Infusion Application of Dissolving Renal Artery Embolic Thrombosis: Low-Dose Slow-Infusion Thrombolytic Therapy
por: Karakurt, Ahmet
Publicado: (2018)

Thrombolytic or endovascular therapy for acute ischemic stroke: Time is brain
por: Mijajlovic, Milija D.
Publicado: (2014)

Repeated Thrombolytic Therapy in Patients with Recurrent Acute Ischemic Stroke
por: Yoo, Han Soo, et al.
Publicado: (2013)

Susceptibility-weighted Imaging in Thrombolytic Therapy of Acute Ischemic Stroke
por: Li, Lin, et al.
Publicado: (2017)

CT-guided thrombolytic treatment of patients with wake-up strokes()
por: Armon, Carmel, et al.
Publicado: (2019)

Temperature-Induced Changes in Reperfused Stroke: Inflammatory and Thrombolytic Biomarkers
por: Ávila-Gómez, Paulo, et al.
Publicado: (2020)

Cholesterol reducer and thrombolytic therapy in acute ischemic stroke patients
por: Poupore, Nicolas, et al.
Publicado: (2020)

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator
por: Ong, Cheung-Ter, et al.
Publicado: (2017)

Half-dose thrombolytic therapy in patients with right heart thrombi
por: Moosavi, Jamal, et al.
Publicado: (2019)

Association of pro-fibrinolytic receptor AnnexinA2 with tissue plasminogen activator/Inhibitor-1 in pre-eclampsia
por: Ruikar, Komal, et al.
Publicado: (2023)

Neuroglobin, a Novel Target for Endogenous Neuroprotection against Stroke and Neurodegenerative Disorders
por: Yu, Zhanyang, et al.
Publicado: (2012)

Stroke severity modified the effect of chronic atrial fibrillation on the outcome of thrombolytic therapy
por: Shao, Rui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4tejse7crlke0r9hqvtsdket1f